

Mitigating Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer (ES-SCLC):

An Expert Roadmap for Optimizing Clinical and Patient-Reported Outcomes

Current Standards of Care in the Treatment of ES-SCLC

NCCN Guidelines: 1st-Line

Preferred Regimens

- **Carboplatin + Etoposide** + Atezolizumab
Followed by Maintenance Atezolizumab
- **Carboplatin + Etoposide** + Durvalumab
Followed by Maintenance Durvalumab
- **Cisplatin + Etoposide** + Durvalumab
Followed by Maintenance Durvalumab

x4 cycles recommended, but can be up to 6 cycles

Other Recommended Regimens

- **Carboplatin + Etoposide**
- **Cisplatin + Etoposide**

Useful in Certain Circumstances

- **Carboplatin + Irinotecan**
- **Cisplatin + Irinotecan**

ASCO Guidelines: 1st-Line

ECOG PS 0-2

Carboplatin or Cisplatin + Etoposide + Immunotherapy x4 Cycles

Maintenance **Immunotherapy**

ECOG PS 3-4 due to SCLC

Carboplatin or Cisplatin + Etoposide x4 Cycles


Consider Maintenance **Immunotherapy if PS Improves**




Sources: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 1.2026 – July 25, 2025; Kalemkerian GP, et al. J Clin Oncol. 2025 Jan;43(1):101-105.

Chemotherapy-Free Interval (CTFI): the period of time a patient receives a break or interruption from chemotherapy treatment. The specific duration of this interval can vary greatly depending on the type of cancer, the individual patient, and the treatment strategy being employed.

NCCN Guidelines: Subsequent-Lines



ASCO Guidelines: Subsequent Lines



Sources: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 1.2026 – July 25, 2025; Kalemkerian GP, et al. J Clin Oncol. 2025 Jan;43(1):101-105.

Chemotherapy-Induced Myelosuppression (CIM) Prophylaxis

NCCN Guidelines

- “**Trilaciclib** or **G-CSF** may be used as prophylactic options to decrease the incidence of CIM when administering platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for ES-SCLC.”
- “GM-CSF or G-CSF are **not recommended** during concurrent systemic therapy + RT.”


ASCO Guidelines

- “May use **trilaciclib** or **G-CSF** if clinically indicated.”

NCCN Hematopoietic Growth Factors Version 1.2025 - October 11, 2024: When platinum/etoposide +/- ICI or a topotecan-containing regimen is used for ES-SCLC, **trilaciclib is recommended as: a prophylactic option to prevent CIM (category 2A) and a prophylactic option to decrease the incidence of anemia and reduce the need for RBC transfusions (category 2B).**

Trilaciclib’s Mechanism of Myeloprotection

**Proactive > Reactive
Multilineage > Single-Lineage**



Trilaciclib is indicated to decrease the incidence of CIM in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC.

Trilaciclib At-A-Glance (Refer to Package Insert for Complete Prescribing Information)

Dosing & Administration	Adverse Events & Warnings/Precautions
<ul style="list-style-type: none"> • Intravenous 240 mg/m² over 30 minutes. • Completed no more than 4 hours prior to the start of chemotherapy. • Administer each day chemotherapy is administered. 	<ul style="list-style-type: none"> • Most common adverse events: fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia. • Warnings/precautions: Injection site reactions, acute drug hypersensitivity reactions, interstitial lung disease/pneumonitis, embryo-fetal toxicity.

Sources: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 1.2026 – July 25, 2025; Kalemkerian GP, et al. J Clin Oncol. 2025 Jan;43(1):101-105; Weiss J, et al. Clin Lung Cancer. 2021; Drugs@FDA: FDA-Approved Drugs. Trilaciclib. August 25, 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214200s006lbl.pdf. Accessed September 2025; NCCN Guidelines. Hematopoietic Growth Factors. Version 1.2025 – October 11, 2024.